| Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer (NCT05200260) | Shanghai Gynecologic Oncology Group | 2022-07-13 |
| A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (NCT05429970) | Memorial Sloan Kettering Cancer Center | 2022-06-17 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer (NCT05200364) | Sutro Biopharma, Inc. | 2022-03-22 |
| Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer (NCT04575961) | North Eastern German Society of Gynaecological Oncology | 2022-02-22 |
| Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer (NCT05236686) | Shanghai Gynecologic Oncology Group | 2022-02-15 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer (NCT05198804) | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 2022-01-27 |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272) | 23andMe, Inc. | 2021-12-29 |
| Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma (NCT05537844) | Liz-Anne Lewsley | 2021-10-27 |
| A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy (NCT04814875) | THERAPIM PTY LTD | 2021-09-01 |
| Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy (NCT03607955) | Washington University School of Medicine | 2021-06-30 |
| Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (NCT04375956) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-04-26 |
| Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) (NCT04515602) | Shanghai Gynecologic Oncology Group | 2021-01-01 |
| National Cancer Institute "Cancer Moonshot Biobank" (NCT04314401) | National Cancer Institute (NCI) | 2020-11-11 |
| A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies (NCT04440943) | Celldex Therapeutics | 2020-08-04 |
| A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy (NCT04229615) | Jiangsu HengRui Medicine Co., Ltd. | 2020-06-02 |
| High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy (NCT04201561) | Seoul National University Hospital | 2019-12-24 |
| Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy (NCT04204811) | Memorial Sloan Kettering Cancer Center | 2019-12-16 |
| Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer) (NCT03891576) | Mario Negri Institute for Pharmacological Research | 2019-11-13 |
| The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer (NCT03921658) | University of Minnesota | 2019-10-22 |
| Phase I Trial HIPEC With Nal-irinotecan (NCT04088786) | Stony Brook University | 2019-10-22 |
| Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) (NCT03983226) | Shanghai Gynecologic Oncology Group | 2019-10-18 |
| Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery (NCT03373058) | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 2019-10-15 |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) (NCT03824704) | pharmaand GmbH | 2019-08-23 |
| Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives (NCT04257045) | M.D. Anderson Cancer Center | 2019-08-21 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study (NCT06274541) | Cancer Trials Ireland | 2019-03-22 |
| HIPEC After Initial CRS in Patients Who Have Received NACT (NCT03540017) | Northwell Health | 2019-03-12 |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (NCT03748186) | Sutro Biopharma, Inc. | 2019-02-01 |
| Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF (NCT03604315) | M.D. Anderson Cancer Center | 2018-12-18 |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer (NCT03783949) | Universitaire Ziekenhuizen KU Leuven | 2018-11-30 |
| MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03585764) | University of Pennsylvania | 2018-10-24 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (NCT03648489) | Imperial College London | 2018-09-21 |
| Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma (NCT03608618) | MaxCyte, Inc. | 2018-08-27 |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC (NCT03363867) | Peter MacCallum Cancer Centre, Australia | 2018-07-10 |
| NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma (NCT06972693) | European Institute of Oncology | 2018-06-12 |
| PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. (NCT03283943) | British Columbia Cancer Agency | 2018-04-01 |
| Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer (NCT03180177) | Shu-Zhong Cui | 2018-03-01 |
| Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT03029403) | University Health Network, Toronto | 2018-02-12 |
| Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas (NCT02033616) | Aivita Biomedical, Inc. | 2017-11-18 |
| Anti-PD-L1 and SAbR for Ovarian Cancer (NCT03312114) | University of Texas Southwestern Medical Center | 2017-11-09 |
| Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer (NCT03297489) | Roswell Park Cancer Institute | 2017-11-06 |
| The Treatment Preferences of Women Diagnosed With Ovarian Cancer (NCT03367260) | Duke University | 2017-10-19 |
| EDMONd - Elemental Diet in Bowel Obstruction (NCT03150992) | Royal Surrey County Hospital NHS Foundation Trust | 2017-07-19 |
| HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life (NCT03000192) | University Hospital Southampton NHS Foundation Trust | 2016-08-01 |
| Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) (NCT02859038) | Shanghai Gynecologic Oncology Group | 2016-08-01 |
| Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers (NCT02725489) | Mary Crowley Medical Research Center | 2016-06-03 |
| Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer (NCT02788708) | Floor Backes | 2016-05-27 |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (NCT02345265) | National Cancer Institute (NCI) | 2016-05-23 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer (NCT02631876) | ImmunoGen, Inc. | 2016-03-02 |
| Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) (NCT02485990) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2016-01-08 |
| Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (NCT02584478) | Advenchen Laboratories, LLC | 2015-12-01 |
| Total/Subtotal Colectomy in Ovarian Cancer (NCT02595021) | Shanghai Gynecologic Oncology Group | 2015-07-01 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies (NCT02578888) | Albert Einstein College of Medicine | 2015-04-01 |
| Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery (NCT02315469) | NRG Oncology | 2015-02-10 |
| A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer (NCT02344095) | Seoul National University Hospital | 2014-12-01 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission (NCT02166905) | Roswell Park Cancer Institute | 2014-10-10 |
| Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (NCT02118285) | Masonic Cancer Center, University of Minnesota | 2014-07-28 |
| HOT: HIPEC in Ovarian Cancer as Initial Treatment (NCT02124421) | Mercy Medical Center | 2014-04-01 |
| Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies (NCT01974765) | Memorial Sloan Kettering Cancer Center | 2013-11-05 |
| Tivozanib As Maintenance Therapy In GYN (NCT01972516) | Dana-Farber Cancer Institute | 2013-11-01 |
| A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian (NCT01952249) | OncoMed Pharmaceuticals, Inc. | 2013-08-05 |
| Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? (NCT01611766) | Shanghai Gynecologic Oncology Group | 2012-07-19 |
| Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma (NCT01519869) | Rachel Miller | 2012-03-01 |
| Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma (NCT02328716) | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | 2012-02-01 |
| Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer (NCT01535157) | South Plains Oncology Consortium | 2012-02-01 |
| Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (NCT01381861) | Tracon Pharmaceuticals Inc. | 2011-07-01 |
| Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma (NCT02217956) | Gustave Roussy, Cancer Campus, Grand Paris | 2011-06-01 |
| Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT01295489) | Gynecologic Oncology Group | 2011-03-01 |
| Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 (NCT01445275) | Gynecologic Oncology Group | 2011-01-01 |
| EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT01118052) | Gynecologic Oncology Group | 2010-11-01 |
| Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (NCT01031381) | University of Pittsburgh | 2010-09-01 |
| Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients (NCT01308944) | Washington University School of Medicine | 2010-08-01 |
| Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer (NCT01180504) | University Hospital Heidelberg | 2010-08-01 |
| Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer (NCT01139957) | Gynecologic Oncology Group | 2010-06-07 |
| N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer (NCT01138137) | OHSU Knight Cancer Institute | 2010-06-01 |
| Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial (NCT01506856) | Gynecologic Oncology Trial & Investigation Consortium | 2010-05-01 |
| Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy (NCT01709487) | Jules Bordet Institute | 2010-05-01 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NCT01097746) | M.D. Anderson Cancer Center | 2010-04-14 |
| Irinotecan and Bevacizumab for Recurrent Ovarian Cancer (NCT01091259) | NYU Langone Health | 2010-03-01 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00989651) | National Cancer Institute (NCI) | 2009-10-28 |
| First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer (NCT01669226) | Shanghai Gynecologic Oncology Group | 2009-04-01 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT00814086) | Gynecologic Oncology Group | 2009-02-01 |
| Study of Ramucirumab in Ovarian Cancer (NCT00721162) | Eli Lilly and Company | 2008-08-01 |
| Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma (NCT00868192) | Washington University School of Medicine | 2008-05-01 |
| Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer (NCT00551070) | National Cancer Institute (NCI) | 2007-12-17 |
| Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy (NCT00551265) | Gynecologic Oncology Group | 2007-10-01 |
| Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors (NCT00561795) | GlaxoSmithKline | 2007-09-01 |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer (NCT00511992) | University of Oklahoma | 2007-07-01 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00499252) | Gynecologic Oncology Group | 2007-06-01 |
| Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors (NCT00301756) | National Cancer Institute (NCI) | 2006-09-01 |
| Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer (NCT00352300) | Gynecologic Oncology Group | 2006-06-01 |
| Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors (NCT00488878) | M.D. Anderson Cancer Center | 2006-05-19 |
| Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer (NCT00322881) | Dana-Farber Cancer Institute | 2006-04-01 |
| Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma (NCT00582205) | University of Oklahoma | 2006-01-01 |
| Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients (NCT00478452) | University of Pennsylvania | 2005-08-01 |
| Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer (NCT00093626) | National Cancer Institute (NCI) | 2004-10-01 |
| Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels (NCT00083928) | Ångstrom Pharmaceuticals | 2004-05-01 |
| Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer (NCT00072566) | National Cancer Institute (NCI) | 2003-12-01 |